Identification of the activating BRAF V600E mutation in a subset of histiocytoses (ECD and LCH, 50-100%) has opened a new avenue for the treatment of these disorders with BRAF and MEK inhibitors [1-5]. Here, MAP2K7 is linked to familial atrioventricular septal defect.